Long-Acting HIV Integrase Inhibitor Suspensions for Monthly Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies for HIV-1 infection require daily adherence, leading to treatment fatigue and potential nonadherence due to the need for frequent administration, necessitating the development of long-acting drug products for improved patient compliance.
Innovation Solution
Pharmaceutical compositions comprising the HIV integrase inhibitor (7S)-12-hydroxy-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide or its pharmaceutically acceptable salts, formulated as long-acting injectable suspensions or nanosuspensions for enhanced tolerability and plasma concentration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If daily antiretroviral therapy is administered to suppress HIV viral replication, then viral suppression and disease progression control are improved, but treatment fatigue and nonadherence increase due to frequent administration requirements
Solution Approach 1:
The patent changes the administration parameter from daily oral intake to monthly injection, fundamentally altering the dosing frequency parameter. This transforms the treatment regimen from requiring daily patient action to a less frequent administrative intervention, directly addressing the adherence problem while maintaining viral suppression through extended pharmacological action.
Solution Approach 2:
The invention transitions from a static daily medication routine to a dynamic injection schedule that provides sustained therapeutic effect over months. The formulation enables the drug to maintain effective concentrations in the body over extended periods, creating a flexible dosing paradigm that adapts to patient needs while reducing frequency requirements.
2Ease of operation
If long-acting injectable formulations are developed to reduce dosing frequency, then adherence is improved, but formulation complexity and manufacturing difficulty increase
Solution Approach 1:
The patent employs a formulation system that acts as an intermediary between the drug substance and the patient. This specialized formulation serves as a vehicle that enables extended-release pharmacokinetics, mediating the interaction between the antiretroviral compound and the body to achieve long-acting effects while managing the complexity through controlled release mechanisms.
Solution Approach 2:
The invention modifies physical and chemical parameters of the drug formulation to achieve extended half-life and sustained release characteristics. By altering parameters such as particle size, formulation matrix composition, and drug release kinetics, the system achieves monthly dosing intervals while containing formulation complexity within manageable parameters.
3Object-affected harmful factors
If injectable formulations are used to improve tolerability and reduce injection site reactions, then patient compliance is enhanced, but manufacturing precision and formulation control requirements increase
Solution Approach 1:
The patent optimizes formulation parameters including particle size distribution, concentration levels, and excipient ratios to minimize local tissue reactions. By precisely controlling these parameters during manufacturing, the formulation achieves reduced injection site reactions while establishing clear manufacturing specifications that manage precision requirements.
Solution Approach 2:
The invention uses standardized formulation protocols and quality control procedures that can be replicated across manufacturing batches. By establishing consistent manufacturing templates and validation protocols, the system ensures reproducible formulation characteristics that reduce variability in tolerability outcomes while streamlining manufacturing precision requirements.
Data Source
AI summary
The present disclosure relates to pharmaceutical compositions (e.g., suspension formulations) including a compound of Formula I:or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable liquid vehicle.Also disclosed are methods of treating or preventing human immunodeficiency virus (HIV) in a human, including administering to the human a pharmaceutical composition disclosed herein.